Synopsis
Synopsis
0
VMF
0
FDA Orange Book
0
Canada
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 4-(((2-amino-3,5-dibromophenyl)methyl)amino)cyclohexanol
2. Abrohexal
3. Am, Bisolvon
4. Ambril
5. Ambro Puren
6. Ambro-puren
7. Ambrobeta
8. Ambrofur
9. Ambrohexal
10. Ambrols
11. Ambrolitic
12. Ambropp
13. Ambropuren
14. Ambroten
15. Ambroxin
16. Ambroxocompren
17. Ambroxol
18. Bisolvon Am
19. Bromhexine Metabolite Viii
20. Bronchopront
21. Bronchowern
22. Broxol
23. Contac Husten Trunk
24. Contac Husten-trunk
25. Contac Hustentrunk
26. Dinobroxol
27. Duramucal
28. Ebromin
29. Expeflen
30. Expit
31. Farmabroxol
32. Flavamed
33. Frenopect
34. Gelopol
35. Hustenlser, Pect
36. Hustenlser, Therapin
37. Larylin Husten Lser
38. Larylin Husten-lser
39. Larylin Hustenlser
40. Lasolvan
41. Metabolite Viii, Bromhexine
42. Mibrox
43. Motosol
44. Muco Fips
45. Muco-fips
46. Mucofips
47. Mucosolvan
48. Mucotablin
49. Na 872
50. Na-872
51. Na872
52. Pdiamuc
53. Pect Hustenlser
54. Pulmonal S
55. Pulmonal, Ringelheimer
56. Ringelheimer Pulmonal
57. Sekretovit
58. Stas Hustenlser
59. Stas-hustenlser
60. Stashustenlser
61. Surbronc
62. Therapin Hustenlser
1. 23828-92-4
2. Ambroxol Hcl
3. Mucoangin
4. Mucosolvan
5. Ambroxolhydrochloride
6. 1384955-66-1
7. 1146648-86-3
8. Lasolvan
9. 15942-05-9
10. Trans-4-((2-amino-3,5-dibromobenzyl)amino)cyclohexanol Hydrochloride
11. Ambroxol Impurity D Hcl
12. 4-((2-amino-3,5-dibromobenzyl)amino)cyclohexan-1-ol Hydrochloride
13. Cis-4-((2-amino-3,5-dibromobenzyl)amino)cyclohexanol Hydrochloride
14. Ambroxol Hydrochloride [jan]
15. Ambroxol Hydrochloride
16. Ambroxol (hydrochloride)
17. Ambroxol Hydrochloride, Cis-
18. 4-[(2-amino-3,5-dibromophenyl)methylamino]cyclohexan-1-ol;hydrochloride
19. Cc995zmv90
20. R3593uz7hs
21. Ambroxol Impurity D Hydrochloride
22. Na-872
23. Mfcd00078932
24. Nsc-758224
25. Ambroxol Hydrochloride (jan)
26. Ambroxol Hydrochloride 100 Microg/ml In Acetonitrile
27. Mucolear
28. Ambroxol Lozenge
29. Cis-4-[(2-amino-3,5-dibromobenzyl)amino]cyclohexanol Hydrochloride
30. Cyclohexanol, 4-(((2-amino-3,5-dibromophenyl)methyl)amino)-, Hydrochloride (1:1), Cis-
31. Smr000875269
32. Na 872 Hydrochloride
33. Ncgc00016781-04
34. Cas-23828-92-4
35. Unii-cc995zmv90
36. Lazolvan
37. Ponophen
38. 4-(2-amino-3,5-dibromobenzylamino)cyclohexanol Hydrochloride
39. Ccris 8686
40. Mucosolvan-l
41. Sr-05000001463
42. Mucosal-l
43. Trans-4-[(2-amino-3,5-dibromobenzyl)amino]cyclohexanol Hydrochloride
44. Hustless (tn)
45. Prestwick_717
46. Einecs 245-899-2
47. Dsstox_cid_25442
48. Dsstox_rid_80883
49. Unii-r3593uz7hs
50. Dsstox_gsid_45442
51. Schembl99455
52. Ambroxol Hydrochloride ,(s)
53. Ambroxol Hydrochloride, 98%
54. Mls001333105
55. Mls001333106
56. Mls002153788
57. Spectrum1503080
58. (e)-4-hdmb
59. Na-872et
60. Chembl1514634
61. Dtxsid2045442
62. Chebi:31198
63. Hy-b1039a
64. Dtxsid60936098
65. Exr-202
66. Hms1569i13
67. Hms1922c19
68. Pharmakon1600-01503080
69. Ambroxol Hydrochloride [mi]
70. 4-((2-amino-3,5-dibromobenzyl)amino)cyclohexanol Hydrochloride
71. Bcp04490
72. Tox21_110607
73. Ac-024
74. Ccg-39174
75. Nsc758224
76. S3064
77. (1r,4r)-4-((2-amino-3,5-dibromobenzyl)amino)cyclohexanol Hydrochloride
78. Akos015895175
79. Akos015951294
80. Akos024462505
81. Ambroxol Hydrochloride [mart.]
82. Ambroxol Hydrochloride [who-dd]
83. Bcp9000284
84. Ccg-220366
85. Ks-5248
86. Nsc 758224
87. Ncgc00016781-03
88. Ncgc00092387-01
89. Ncgc00094999-01
90. Ncgc00094999-02
91. Ba166015
92. Sy052506
93. Ambroxol Hydrochloride, Analytical Standard
94. Bcp0726000073
95. Ambroxol Hydrochloride [ep Impurity]
96. Ambroxol Hydrochloride [ep Monograph]
97. B2267
98. Cs-0013219
99. Ft-0630506
100. Sw198832-2
101. A16398
102. D01479
103. H11915
104. A816928
105. Sr-01000837516
106. Q-100980
107. Sr-01000837516-3
108. Sr-05000001463-2
109. Q27275396
110. Ambroxol Hydrochloride Pound Ep2001/cp2000 Pound(c)
111. F1131-0002
112. Ambroxol Hydrochloride 1.0 Mg/ml In Methanol (as Free Base)
113. Trans-4-(2-amino-3,5-dibromobenzylamino)cyclohexanol Hydrochloride
114. (1r,4r)-4-((2-amino-3,5-dibromobenzyl)amino)cyclohexan-1-ol Hydrochloride
115. (1r,4r)-4-(2-amino-3,5-dibromobenzylamino)cyclohexanol Hydrochloride
116. 4-[(2-amino-3,5-dibromobenzyl)amino]cyclohexanol Hydrochloride, Aldrichcpr
117. Ambroxol Hydrochloride, European Pharmacopoeia (ep) Reference Standard
118. Cyclohexanol, 4-((2-amino-3,5-dibromobenzyl)amino)-, Hydrochloride, Trans-
119. Cyclohexanol, 4-(n-(2-amino-3,5-dibromobenzyl)amino)-, Hydrochloride (e)-
120. Cyclohexanol, 4-[[(2-amino-3,5-dibromophenyl)methyl]amino]-, Hydrochloride
121. Cyclohexanol,4-[[(2-amino-3,5-dibromophenyl)methyl]amino]-,hydrochloride
122. Trans-4-((2-amino-3,5-dibromobenzyl)-amino)cyclohexanol Hydrochloride
123. 4-{[(2-amino-3,5-dibromophenyl)methyl]amino}cyclohexan-1-ol--hydrogen Chloride (1/1)
124. Cyclohexanol, 4-(((2-amino-3,5-dibromophenyl)methyl)amino)-, Monohydrochloride, Trans-
125. Cyclohexanol, 4-[[(2-amino-3,5-dibromophenyl)methyl]amino]-, Hydrochloride (1:1), Trans-
126. Imp. D (ep): Cis-4-[(2-amino-3,5-dibromobenzyl)amino]-cyclohexanol Hcl
127. Trans-4-(((2-amino-3,5-dibromophenyl)methyl)amino)cyclohexan-1-ol Hydrochloride
128. Trans-4-[[(2-amino-3,5-dibromo-phenyl)methyl]amino]-cyclohexanol Hydrochloride
129. Trans-4-[[(2-amino-3,5-dibromophenyl)methyl]amino]cyclohexanol Hydrochloride
| Molecular Weight | 414.56 g/mol |
|---|---|
| Molecular Formula | C13H19Br2ClN2O |
| Hydrogen Bond Donor Count | 4 |
| Hydrogen Bond Acceptor Count | 3 |
| Rotatable Bond Count | 3 |
| Exact Mass | 413.95322 g/mol |
| Monoisotopic Mass | 411.95527 g/mol |
| Topological Polar Surface Area | 58.3 Ų |
| Heavy Atom Count | 19 |
| Formal Charge | 0 |
| Complexity | 259 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
Expectorants
Agents that increase mucous excretion. Mucolytic agents, that is drugs that liquefy mucous secretions, are also included here. (See all compounds classified as Expectorants.)
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CEP/COS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATE SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
41
PharmaCompass offers a list of Ambroxol Hydrochloride API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Ambroxol Hydrochloride manufacturer or Ambroxol Hydrochloride supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Ambroxol Hydrochloride manufacturer or Ambroxol Hydrochloride supplier.
PharmaCompass also assists you with knowing the Ambroxol Hydrochloride API Price utilized in the formulation of products. Ambroxol Hydrochloride API Price is not always fixed or binding as the Ambroxol Hydrochloride Price is obtained through a variety of data sources. The Ambroxol Hydrochloride Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Lasolvan manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Lasolvan, including repackagers and relabelers. The FDA regulates Lasolvan manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Lasolvan API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Lasolvan manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Lasolvan supplier is an individual or a company that provides Lasolvan active pharmaceutical ingredient (API) or Lasolvan finished formulations upon request. The Lasolvan suppliers may include Lasolvan API manufacturers, exporters, distributors and traders.
click here to find a list of Lasolvan suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Lasolvan DMF (Drug Master File) is a document detailing the whole manufacturing process of Lasolvan active pharmaceutical ingredient (API) in detail. Different forms of Lasolvan DMFs exist exist since differing nations have different regulations, such as Lasolvan USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Lasolvan DMF submitted to regulatory agencies in the US is known as a USDMF. Lasolvan USDMF includes data on Lasolvan's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Lasolvan USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Lasolvan suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Lasolvan Drug Master File in Japan (Lasolvan JDMF) empowers Lasolvan API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Lasolvan JDMF during the approval evaluation for pharmaceutical products. At the time of Lasolvan JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Lasolvan suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Lasolvan Drug Master File in Korea (Lasolvan KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Lasolvan. The MFDS reviews the Lasolvan KDMF as part of the drug registration process and uses the information provided in the Lasolvan KDMF to evaluate the safety and efficacy of the drug.
After submitting a Lasolvan KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Lasolvan API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Lasolvan suppliers with KDMF on PharmaCompass.
A Lasolvan CEP of the European Pharmacopoeia monograph is often referred to as a Lasolvan Certificate of Suitability (COS). The purpose of a Lasolvan CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Lasolvan EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Lasolvan to their clients by showing that a Lasolvan CEP has been issued for it. The manufacturer submits a Lasolvan CEP (COS) as part of the market authorization procedure, and it takes on the role of a Lasolvan CEP holder for the record. Additionally, the data presented in the Lasolvan CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Lasolvan DMF.
A Lasolvan CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Lasolvan CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Lasolvan suppliers with CEP (COS) on PharmaCompass.
A Lasolvan written confirmation (Lasolvan WC) is an official document issued by a regulatory agency to a Lasolvan manufacturer, verifying that the manufacturing facility of a Lasolvan active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Lasolvan APIs or Lasolvan finished pharmaceutical products to another nation, regulatory agencies frequently require a Lasolvan WC (written confirmation) as part of the regulatory process.
click here to find a list of Lasolvan suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Lasolvan as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Lasolvan API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Lasolvan as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Lasolvan and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Lasolvan NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Lasolvan suppliers with NDC on PharmaCompass.
Lasolvan Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Lasolvan GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Lasolvan GMP manufacturer or Lasolvan GMP API supplier for your needs.
A Lasolvan CoA (Certificate of Analysis) is a formal document that attests to Lasolvan's compliance with Lasolvan specifications and serves as a tool for batch-level quality control.
Lasolvan CoA mostly includes findings from lab analyses of a specific batch. For each Lasolvan CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Lasolvan may be tested according to a variety of international standards, such as European Pharmacopoeia (Lasolvan EP), Lasolvan JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Lasolvan USP).
